Cancer
Cancer Ongoing 2020 Michigan: Maria Pappas (248) 553-0606

CC003

A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer

Trial overview

Disease
Lung cancer treatment and diagnosis
Topic
CC003
Description
Primary Objective:To determine whether the 12-month intracranial relapse rate following HA-PCI is non-inferior compared to the rate following PCI for patients with SCLC. To determine whether HA-PCI reduces the likelihood of 6-month deterioration from baseline in HVLT-R delayed recall compared to the PCI for patients with SCLC.Patient Population:Histologic proof or unequivocal cytologic proof (fine needle aspiration, biopsy or two positive sputa) of SCLC within 250 days prior to Step 1 registration; Zubrod performance status 0-2; Patients who are primary English or French speakers are eligible.
Physicians

Dr. Alvaro A. Martinez

MD, FACR, FABS, FASTRO

Radiation Oncologist

Works at 5 centers.

Dr. Frank A. Vicini

MD, FACR, FASTRO

Radiation oncologist

Works at 3 centers.

Dr. Larry L. Kestin

MD, FACR

Radiation Oncologist

Works at 3 centers.

Dr. Thomas Boike

MD

Radiation Oncologist

Works at 3 centers.

Dr. Michael I. Ghilezan

MD, PhD

Radiation Oncologist

Works at 4 centers.

Dr. John Vito Antonucci

MD

Radiation Oncologist

Works at 4 centers.